View : 132 Download: 0
Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
- Title
- Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
- Authors
- Kim, Yu Ri; Kim, Jin Seok; Kim, Won Seog; Eom, Hyeon Seok; Yang, Deok-Hwan; Bae, Sung Hwa; Kim, Hyo Jung; Lee, Jae Hoon; Oh, Suk-Joong; Yoon, Sung-Soo; Kwak, Jae-Yong; Choi, Chul Won; Kim, Min Kyoung; Oh, Sung Young; Kang, Hye Jin; Nam, Seung Hyun; Shim, Hyeok; Park, Joon Seong; Mun, Yeung-Chul; Suh, Cheolwon|Korean Soc Hematology Lymphoma Wor
- Ewha Authors
- 문영철
- SCOPUS Author ID
- 문영철
- Issue Date
- 2023
- Journal Title
- CANCER RESEARCH AND TREATMENT
- ISSN
- 1598-2998
2005-9256
- Citation
- CANCER RESEARCH AND TREATMENT vol. 55, no. 4, pp. 1355 - 1362
- Keywords
- Key words Rituximab; Diffuse large B-cell lymphoma; R-CHOP; Response
- Publisher
- KOREAN CANCER ASSOCIATION
- Indexed
- SCIE; SCOPUS; KCI
- Document Type
- Article
- Abstract
- Purpose This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL). Materials and Methods Ninety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of RCHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy. Results Among the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent >= grade 3 adverse events (40.0%) and five treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016). Conclusion Rituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients (ClinicalTrials.gov ID: NCT01054781).
- DOI
- 10.4143/crt.2023.271
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML